NuCana plc (NCNA) and Aileron Therapeutics Inc. (NASDAQ:ALRN) Contrasting side by side

As Biotechnology businesses, NuCana plc (NASDAQ:NCNA) and Aileron Therapeutics Inc. (NASDAQ:ALRN), are affected by contrast. This especially applies to their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NuCana plc N/A 0.00 N/A -0.58 0.00
Aileron Therapeutics Inc. N/A 0.00 31.38M -2.13 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 shows NuCana plc and Aileron Therapeutics Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
NuCana plc 0.00% 0% 0%
Aileron Therapeutics Inc. 0.00% -85% -70%

Liquidity

The Current Ratio and Quick Ratio of NuCana plc are 21.2 and 21.2 respectively. Its competitor Aileron Therapeutics Inc.’s Current Ratio is 2.5 and its Quick Ratio is 2.5. NuCana plc can pay off short and long-term obligations better than Aileron Therapeutics Inc.

Insider & Institutional Ownership

NuCana plc and Aileron Therapeutics Inc. has shares owned by institutional investors as follows: 38.5% and 20.6%. Insiders owned 15.48% of NuCana plc shares. Insiders Competitively, owned 16.4% of Aileron Therapeutics Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
NuCana plc -9.59% 10.96% -24.86% -36.69% 51.9% 74.28%
Aileron Therapeutics Inc. -7.83% -2.44% -34.85% -62.83% -80.2% -81.02%

For the past year NuCana plc has 74.28% stronger performance while Aileron Therapeutics Inc. has -81.02% weaker performance.

Summary

NuCana plc beats Aileron Therapeutics Inc. on 6 of the 6 factors.

NuCana plc, a biopharmaceutical company, engages in the development of products for the treatment of cancer. The company is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; that is in Phase Ib clinical trials for the treatment of recurrent ovarian cancer; in Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer. The company is also developing NUC-3373, which is in Phase I clinical trials for the treatment of patients with advanced solid tumors, as well as for the treatment of colorectal and breast cancer; and NUC-7738, a nucleoside analog that is in preclinical studies for the treatment of solid tumors and hematology. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. The company was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing a novel class of therapeutics in the United States. The companyÂ’s lead product includes ALRN-6924, a stapled peptide that in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial for the treatment of peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase II b trial for the treatment of AML/MDS in combination with cytosine arabinoside. It is also developing next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.